Search
for
Sort by
Research 511–540 of 1000+
- Alopecia Areata
- Sexual dysfunction, including hypoactive sexual desire disorder: Diagnosis and treatment recommendations
- Minoxidil to Treat Androgenetic Alopecia in Men and Women: What is It & How does It Work?
- Cepharanthine: a review of the antiviral potential of a Japanese-approved alopecia drug in COVID-19
- Safety profile of ipilimumab in elderly patients: a disproportionate analysis based on the FDA Adverse Event Reporting System database
- Answer of Regenerative Therapy Not Hair Treatment Patients with Androgenetic Alopecia Approved for Hairmetrix® Technology - Case Report
- US clinics marketing unproven and unlicensed adipose-derived autologous stem cell interventions
- FDA approval of Deuruxolitinib: A New Treatment Option for Severe Alopecia Areata
- Upadacitinib in dermatologic therapy: Emerging evidence and expanding indications
- Lasers in Hair Growth and Hair Transplantation
- Low‐level laser (light) therapy (LLLT) for treatment of hair loss
- Safety Assessment of Ritlecitinib Based on the FDA Adverse Event Reporting System (FAERS) Database: A Real‐World Pharmacovigilance Study
- Suicidality Risks Associated with Finasteride, a 5-Alpha Reductase Inhibitor: An Evaluation of Real-World Data from the FDA Adverse Event Reports
- Multidimensional assessment of adverse events of finasteride:a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024
- Practical Geriatrics: Maintaining Sexual Health After Menopause
- Adverse events associated with vismodegib: insights from a real-world pharmacovigilance study using the FAERS database
- Androgenetic alopecia (male pattern hair loss) in the United States: What treatments should primary care providers recommend?
- Evaluation of dermatologic adverse events associated with aromatase inhibitors: insights from the FAERS database
- Hair Care Cosmetics Regulation in Different Countries – A Comparative Study
- A History of Drug Advertising: The Evolving Roles of Consumers and Consumer Protection
- Persistent Sexual Dysfunction and Suicidal Ideation in Young Men Treated with Low-Dose Finasteride: A Pharmacovigilance Study
- Impact of Reporter Type on Signal Detection of Cancer Therapy-Induced Alopecia: A Hypothesis-Generating Study Using the FDA Adverse Event Reporting System
- Impact of Reporter Type on Signal Detection of Cancer Therapy–Induced Alopecia: A Hypothesis-Generating Study Using the FDA Adverse Event Reporting System
- Low‐Dose Oral Minoxidil and Associated Adverse Events: Analyses of the FDA Adverse Event Reporting System (FAERS) With a Focus on Pericardial Effusions
- Synthesis and application of clinically approved small-molecule drugs targeting androgen receptor
- A Real‐World Disproportionality Analysis of Avacopan in Anti‐Neutrophil Cytoplasmic Antibodies Associated Vasculitis: Insights From FDA Adverse Event Reporting System
- Adverse event reporting of four anti-Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system
- Ovary and uterus related adverse events associated with statin use: an analysis of the FDA Adverse Event Reporting System
- Innovations in skin microphysiological systems for nonclinical testing and FDA modernization
- The Effects of Lower vs Higher Cell Number of Platelet-Rich Plasma (PRP) on Hair Density and Diameter in Androgenetic Alopecia (AGA): A Randomized, Double-Blinded, Placebo, Parallel-Group Half-Scalp IRB-Approved Study.